Biotech Startups

Rhelixa provides genomic and epigenomic analysis services and consulting to life science researchers, as well as a cloud-based research support platform for medical and biological research. The company also conducts research and development related to anti-aging.

1 investor

Rheon Medical develops novel surgical devices to treat glaucoma, aiming to improve treatment efficacy and reduce post-operative complications for patients. The company is a spin-off from EPFL and combines engineering expertise with clinical guidance from ophthalmology specialists.

1 investor

Rho Bio is a biotechnology company focused on lymphatic flow, developing therapeutics related to the lymphatic system.

1 investor

RhoDx develops cell-free DNA and RNA enrichment technologies for liquid biopsy cancer diagnostics. The company provides ultra-sensitive mutation detection methods to improve the performance and accessibility of liquid biopsy testing.

1 investor

Ribogenyx develops first-in-class therapeutic enhancers of translational fidelity, targeting mRNA translation processes for precision medicine. Its focus is on age-related diseases and mechanisms of stress resilience mediated by mRNA translation.

1 investor

Ribo Science is a biopharmaceutical company focused on discovering and developing novel ribose-based molecules for treating human cancers and viral diseases. The company combines scientific research with technical expertise to design first-in-class therapeutic treatments.

1 investor

Riboway Therapeutics develops RNA-targeting technology powered by AI to control protein expression for therapeutic purposes. The company focuses on treating neurodegenerative and metabolic diseases, with programs including an antisense oligonucleotide targeting Spinocerebellar Ataxia Type 2.

1 investor

Rift Protein develops plant-based protein ingredients sourced from smallholder farmers in East Africa and Europe, with plans to expand into precision fermentation. The company supplies plant protein for food production using renewable energy and local processing facilities.

1 investor

RIGImmune is a biotechnology company developing stem loop RNA (SLR) therapeutics that activate the RIG-I innate immune sensor and the Type I interferon pathway for use against serious respiratory diseases. It operates a non-lipid-nanoparticle delivery platform called NEED (Nano-Emulsion Enhanced Delivery) for delivering RNA therapeutics directly to the respiratory tract.

1 investor

RIN Institute develops antibody-based pharmaceuticals and in vitro diagnostic drugs for medical research and clinical use. The company was spun out from Japan's National Cancer Center.

1 investor

Ritivel builds an AI-native platform that automates regulatory workflows and documentation for life sciences companies, helping accelerate the submission of therapies to patients.

1 investor

River Biomedics develops human cardiac in vitro models used for drug target and compound validation, building a pipeline of cardiac therapies. It focuses on treatments for cardiac diseases by targeting biological processes involved in their pathology.

1 investor

RiverD designs and manufactures non-invasive skin analysis devices based on Raman spectroscopy technology for scientific research, clinical applications, and industrial use. The company's instruments provide precise insights into skin composition and topical product penetration.

1 investor

Rivia provides a unified clinical trial data platform that helps biotechnology companies accelerate drug development and reduce costs through technology-enabled solutions for managing complex trial operations. The platform serves biotech firms bringing new therapies to market.

1 investor

RK Pharma Inc is a US-based generic pharmaceutical group that develops, manufactures, and sells generic drugs, active pharmaceutical ingredients, and injectable, sterile ophthalmic, and dermal products, with a focus on formulation-challenged and first-generic opportunities. It operates through subsidiaries in the US and India, serving the worldwide pharmaceutical industry.

1 investor

RNA Connect develops uMRT, a reverse transcriptase enzyme for end-to-end cDNA synthesis that copies full RNA transcripts, including large viral genomes, in a single pass. The technology is aimed at gene expression, regulation, and discovery research applications in the life sciences.

1 investor

RNAiSSANCE AG develops RNAi-based solutions for agricultural pest control, using biomanufacturing, strain development, and entomology research. The company focuses on discovery and production of RNA interference technology for crop protection.

1 investor

Develops precision RNA-based gene-regulating therapies aimed at treating serious diseases.

1 investor

Roca Therapeutics develops first-in-class small molecule therapies for patients with neovascular retinal diseases. Founded in 2021 as a spin-off from Nice University and SATT Sud Est, the company is a biotech focused on ophthalmology drug development based in Nice, France.

1 investor

1 investor

Roka Bioscience develops molecular testing assays and automated instrument systems for rapid pathogen detection in food manufacturing. The company serves food safety professionals and manufacturers seeking to reduce contamination risks and improve laboratory efficiency.

1 investor

Roka Furadada is a Barcelona-based deep biotech company that develops patented solar active ingredients for the cosmetics industry, including a photo-adaptive UVA absorber and upcycled lignin-based multifunctional actives for skin, sun, and hair care. It co-creates products with formulators, R&D leads, and marketing teams at cosmetics brands, guiding them from molecular design to market launch across global markets.

1 investor

Rondo Therapeutics develops immune-engaging bispecific antibodies designed to treat solid tumors with tuned immune-activating arms and tumor-localized activity to reduce side effects. It uses an NGS-based antibody discovery platform to build binding-arm libraries and advance a pipeline of cancer therapeutics for indications such as bladder, ovarian, endometrial, and renal cancers.

1 investor

Rosalind is a cloud-based bioinformatics platform that enables scientists to analyze next-generation sequencing (NGS) data without programming expertise, delivering results same-day with collaboration tools. The platform serves pharma, biotech, and academic researchers for genomics analysis including bulk RNA-seq, single-cell expression, ChIP-seq, and ATAC-seq workflows.

1 investor